The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2022 | Venetoclax-based combinations in patients with accelerated and blast-phase MPNs
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly comments on the use of venetoclax-based combinations in patients with accelerated and blast-phase myeloproliferative neoplasms (MPNs) and the need to further evaluate the best approach to using these combinations. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
